Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENURONE vs VERSED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.
Adjunctive therapy in the treatment of partial seizures with or without secondary generalization,Off-label: refractory epilepsy, complex partial seizures
Sedation,Anxiolysis,Amnesia,Induction of anesthesia,Maintenance of anesthesia,ICU sedation,Status epilepticus (off-label)
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Terminal elimination half-life: 1.8–2.5 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity (up to 8 hours), hepatic cirrhosis (up to 20 hours), and critically ill patients.
Primarily hepatic metabolism via hydrolysis and conjugation; involves CYP450 enzymes (minor contribution). Metabolites are excreted in urine.
Hepatic via CYP3A4 isoenzymes; major metabolites include midazolam glucuronide (inactive) and alpha-hydroxymidazolam (active).
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Renal: ~1% unchanged; Hepatic metabolism to glucuronide conjugates and 1-hydroxymidazolam, with subsequent renal elimination of metabolites. Fecal excretion is minimal (<2%).
Approximately 80-90% bound, primarily to serum albumin. The binding is saturable, which can lead to nonlinear pharmacokinetics at high doses.
97% bound primarily to albumin.
0.5-1.0 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding. Vd may be increased in epilepsy or with co-administration of other anticonvulsants.
1–1.5 L/kg (0.5–1.2 L/kg in adults); increased in obesity and hepatic disease, indicating extensive tissue distribution.
Oral bioavailability is approximately 90-100% based on absorption studies. Food does not significantly affect absorption.
IM: 90%±; Oral: 40–50% (range 30–70%); Intranasal: ~75%; Rectal: ~50%.
No specific guidelines; use with caution in renal impairment. Monitor for toxicity.
e GFR 10-50 m L/min: No dose adjustment needed but monitor for prolonged sedation. e GFR <10 m L/min: Consider 50% dose reduction and monitor closely.
Child-Pugh Class A: No adjustment; Class B: Reduce dose by 25-50%; Class C: Avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce dose by 75%.
Children: 10-20 mg/kg/day orally in 2-3 divided doses; maximum 1.5 g/day.
Neonates: IV 0.05-0.1 mg/kg; max 0.15 mg/kg. Children: IV 0.025-0.05 mg/kg (max 2 mg); titrate. Oral 0.25-0.5 mg/kg (max 20 mg) for sedation. IM 0.07-0.08 mg/kg.
Initiate at low end of dosing range (500 mg/day) and titrate slowly; monitor for neurotoxicity.
IV: Initial 0.5-1 mg over 2 minutes; titrate slowly; max total dose 3.5 mg. Oral: 5 mg preoperatively. Reduced clearance necessitates careful titration.
Phenacemide may cause fatal hepatotoxicity and aplastic anemia. Patients must be closely monitored for signs of hepatic dysfunction and blood dyscrasias.
Intravenous administration may cause respiratory depression and arrest, especially when used with opioids. Resuscitation equipment and skilled personnel must be available. Do not administer by rapid bolus injection.
Hepatotoxicity: monitor liver function tests at baseline and periodically; discontinue if signs of hepatic injury. Aplastic anemia: advise patients to report unexplained bleeding, bruising, or signs of infection. Suicidal ideation: monitor for changes in mood or behavior. Withdrawal: do not discontinue abruptly.
Respiratory depression, hypotension, paradoxical reactions, dependence and withdrawal, use in elderly or debilitated patients, hepatic/renal impairment, myasthenia gravis, glaucoma, pregnancy (category D).
History of liver disease or hepatic dysfunction. History of aplastic anemia or bone marrow depression. Hypersensitivity to phenacemide or other hydantoins. Concurrent use with other hepatotoxic drugs.
Known hypersensitivity to benzodiazepines, acute narrow-angle glaucoma, severe respiratory insufficiency (COPD), pregnancy (labor and delivery), breastfeeding (caution).
No significant food interactions documented. Avoid alcohol entirely due to additive CNS depression and potential hepatotoxicity.
Grapefruit juice inhibits CYP3A4 and can significantly increase midazolam plasma concentrations, prolonging sedation and respiratory depression. Avoid grapefruit products for at least 24 hours before and after administration. High-fat meals may reduce absorption rate but not extent, though clinical significance is minimal.
Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.
Midazolam is classified as FDA Pregnancy Category D. There is evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. First trimester exposure may be associated with an increased risk of congenital malformations (e.g., cleft palate). Second and third trimester exposure may cause fetal CNS depression, respiratory depression, and withdrawal symptoms (floppy infant syndrome). Use during labor may cause neonatal respiratory depression and hypotonia. Maternal hypotension and decreased uterine blood flow may occur.
Excreted into breast milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects (e.g., sedation, poor feeding) in the infant.
Midazolam is excreted in human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05 to 0.15. Relative infant dose is estimated to be <1% of maternal weight-adjusted dose. Due to potential for accumulation and CNS effects in the neonate, caution is advised; alternative agents with shorter half-lives and no active metabolites are preferred. Use only if clearly needed and monitor infant for sedation, poor feeding, and respiratory depression.
Due to increased clearance in pregnancy, monitor serum concentrations and adjust dose to maintain therapeutic levels; may require dose increases by 20-30%.
No specific standardized dose adjustments are established for pregnancy. Due to increased volume of distribution and altered protein binding, higher or more frequent doses may be required to achieve the same clinical effect. However, increased sensitivity to CNS depression and respiratory depression in pregnancy may offset this, requiring careful titration. Avoid use in first trimester if possible. Use lowest effective dose for shortest duration. During labor, use reduced doses due to potential for fetal accumulation and neonatal respiratory depression.
Phenurone (phenacemide) is a last-line anticonvulsant due to high risk of hepatotoxicity and bone marrow suppression. Monitor LFTs and CBC monthly. Avoid in patients with liver disease or history of psychosis. Therapeutic drug monitoring: target serum phenacemide level 5-12 mcg/m L. May cause severe personality changes and suicidal ideation.
Midazolam (Versed) is a short-acting benzodiazepine used for procedural sedation, pre-anesthetic medication, and status epilepticus. It has amnestic properties. Onset is rapid (1-2 min IV, 15-30 min IM). Flumazenil is the reversal agent. Caution in elderly, hepatic impairment, and respiratory compromise. CYP3A4 inhibitors (e.g., macrolides, azole antifungals, grapefruit juice) increase levels. Not recommended for prolonged sedation in ICU due to active metabolites and accumulation.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report signs of liver injury (yellow skin/eyes, dark urine, abdominal pain) or blood dyscrasias (fever, sore throat, easy bruising) immediately.,Avoid alcohol completely while taking this medication.,May cause drowsiness or dizziness; avoid driving until you know how this drug affects you.,Use reliable contraception; phenacemide can harm a fetus and decrease effectiveness of hormonal contraceptives.,Do not stop abruptly; withdrawal can precipitate seizures.
You may experience drowsiness, dizziness, or amnesia after receiving this medication.,Do not drive or operate heavy machinery for at least 24 hours after the procedure.,Avoid alcohol for at least 24 hours after receiving midazolam.,Grapefruit and grapefruit juice may increase the effects of midazolam; avoid consumption.,Inform your healthcare provider if you are pregnant, breastfeeding, or have a history of glaucoma or breathing problems.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENURONE vs VERSED, answered by our medical review team.
PHENURONE is a Anticonvulsant that works by Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.. VERSED is a Benzodiazepine that works by Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENURONE and VERSED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENURONE is: Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.. The standard adult dose of VERSED is: IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENURONE and VERSED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENURONE is classified as Category C. Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.. VERSED is classified as Category C. Midazolam is classified as FDA Pregnancy Category D. There is evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.